EA201100748A1 - Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10 - Google Patents
Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10Info
- Publication number
- EA201100748A1 EA201100748A1 EA201100748A EA201100748A EA201100748A1 EA 201100748 A1 EA201100748 A1 EA 201100748A1 EA 201100748 A EA201100748 A EA 201100748A EA 201100748 A EA201100748 A EA 201100748A EA 201100748 A1 EA201100748 A1 EA 201100748A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- phosphodesterase
- inhibitors
- pyrazine compounds
- compounds
- pyrazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Представлены пиразиновые соединения и композиции, содержащие их, и способ получения таких соединений. В данной заявке также представлены способы лечения расстройств или заболеваний, которые можно лечить путем ингибирования PDE10, таких как ожирение, инсулиннезависимый диабет, шизофрения, биполярное расстройство, обсессивно-компульсивное расстройство и т.п.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11456708P | 2008-11-14 | 2008-11-14 | |
US16621209P | 2009-04-02 | 2009-04-02 | |
PCT/US2009/064637 WO2010057121A1 (en) | 2008-11-14 | 2009-11-16 | Pyrazine compounds as phosphodiesterase 10 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201100748A1 true EA201100748A1 (ru) | 2011-10-31 |
EA019206B1 EA019206B1 (ru) | 2014-01-30 |
Family
ID=41478512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201100748A EA019206B1 (ru) | 2008-11-14 | 2009-11-16 | Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10 |
Country Status (31)
Country | Link |
---|---|
US (4) | US8053438B2 (ru) |
EP (1) | EP2364308B1 (ru) |
JP (1) | JP5746972B2 (ru) |
KR (1) | KR20110083746A (ru) |
CN (1) | CN102300860B (ru) |
AR (1) | AR074358A1 (ru) |
AU (1) | AU2009313768B2 (ru) |
BR (1) | BRPI0922095A2 (ru) |
CA (1) | CA2742993C (ru) |
CL (1) | CL2011001094A1 (ru) |
CO (1) | CO6382157A2 (ru) |
CR (1) | CR20110326A (ru) |
CY (1) | CY1113680T1 (ru) |
DK (1) | DK2364308T3 (ru) |
EA (1) | EA019206B1 (ru) |
ES (1) | ES2397218T3 (ru) |
HK (1) | HK1161251A1 (ru) |
HR (1) | HRP20130054T1 (ru) |
IL (1) | IL212687A0 (ru) |
MA (1) | MA32889B1 (ru) |
MX (1) | MX2011005100A (ru) |
NZ (1) | NZ592508A (ru) |
PE (1) | PE20110581A1 (ru) |
PL (1) | PL2364308T3 (ru) |
PT (1) | PT2364308E (ru) |
RS (1) | RS52598B (ru) |
SI (1) | SI2364308T1 (ru) |
SM (1) | SMT201200061B (ru) |
TN (1) | TN2011000221A1 (ru) |
TW (1) | TWI396689B (ru) |
WO (1) | WO2010057121A1 (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
ES2397934T3 (es) * | 2008-12-17 | 2013-03-12 | Amgen Inc. | Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 |
EP3006031A1 (en) | 2009-02-05 | 2016-04-13 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
CA2760837C (en) * | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
SG183321A1 (en) | 2010-02-19 | 2012-09-27 | Boehringer Ingelheim Int | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
KR101875238B1 (ko) | 2010-06-24 | 2018-07-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 포스포디에스테라아제 (pdes) 저해제로서의 융합 헤테로시클릭 화합물 |
EP2601192B1 (en) * | 2010-08-04 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
JP5785548B2 (ja) | 2010-08-04 | 2015-09-30 | 武田薬品工業株式会社 | 縮合複素環化合物 |
EP2604597B1 (en) | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a |
EP2640708A1 (en) | 2010-11-19 | 2013-09-25 | Ligand Pharmaceuticals Inc. | Heterocycle amines and uses thereof |
ES2627788T3 (es) | 2011-01-11 | 2017-07-31 | Sunovion Pharmaceuticals Inc. | Compuestos heteroarilo y procedimientos de uso de los mismos |
US9029388B2 (en) | 2011-03-16 | 2015-05-12 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
TWI570122B (zh) | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
CA2922849A1 (en) * | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
CN102911135B (zh) * | 2012-10-18 | 2016-01-13 | 内蒙古工业大学 | 2-巯基苯并噻唑类衍生物的合成方法 |
US9149533B2 (en) | 2013-02-05 | 2015-10-06 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9464076B2 (en) | 2013-03-15 | 2016-10-11 | Daiichi Sankyo Company, Limited | Benzothiophene derivative |
WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
WO2015048281A1 (en) | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
CN104649882A (zh) * | 2015-02-11 | 2015-05-27 | 南通恒盛精细化工有限公司 | 一种磷酸二酯酶抑制剂的中间体制备工艺 |
US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
EP3351533A4 (en) * | 2015-09-18 | 2019-03-06 | Kaken Pharmaceutical Co., Ltd. | BIARY DERIVATIVE AND MEDICAMENT THEREOF |
KR20200112908A (ko) * | 2018-01-19 | 2020-10-05 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | 헤테로시클릭 화합물, 제조 방법 및 의약품에서의 이의 용도 |
CN109020977B (zh) * | 2018-10-26 | 2020-11-13 | 安庆奇创药业有限公司 | 一种Acalabrutinib的制备方法 |
WO2022129018A1 (en) | 2020-12-17 | 2022-06-23 | Merck Patent Gmbh | Heteroaromatic isothiocyanates |
CN113929598A (zh) * | 2021-11-24 | 2022-01-14 | 上海吉奉生物科技有限公司 | 一种(s)-2-叔丁氧羰基氨基-3-(4,4-二氟环己基)丙酸的合成方法 |
CN117024405A (zh) * | 2022-05-09 | 2023-11-10 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
CN115894181A (zh) * | 2022-09-30 | 2023-04-04 | 渭南高新区海泰新型电子材料有限责任公司 | 一种环己烯基环己基二氟苯类液晶化合物的合成方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
MXPA05010627A (es) | 2003-04-04 | 2005-12-12 | Lundbeck & Co As H | Derivados de 4-(2-feniloxifenil)-piperidina o 1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina. |
DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
JP4584990B2 (ja) * | 2004-05-18 | 2010-11-24 | シェーリング コーポレイション | Pde4インヒビターとして有用な置換2−キノリル−オキサゾール |
WO2005120514A1 (en) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
DE102005016634A1 (de) * | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
KR20080031997A (ko) | 2005-08-02 | 2008-04-11 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 5-치환 티아졸-2-일 아미노화합물 및 조성물 |
AU2007217750A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
WO2007129183A2 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
US8236823B2 (en) | 2006-10-27 | 2012-08-07 | Amgen Inc. | Multi-cyclic compounds and methods of use |
KR20090092338A (ko) * | 2006-12-21 | 2009-08-31 | 화이자 프로덕츠 인크. | 2-((4-(1-메틸-4-(피리딘-4-일)-1h-피라졸-3-일)페녹시)메틸)퀴놀린의 숙시네이트 염 |
CN101910158A (zh) | 2007-10-25 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物 |
WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
JP2011524917A (ja) | 2008-06-20 | 2011-09-08 | メタボレックス, インコーポレイテッド | アリールgpr119作動薬およびその使用 |
-
2009
- 2009-11-13 TW TW098138718A patent/TWI396689B/zh not_active IP Right Cessation
- 2009-11-16 SI SI200930429T patent/SI2364308T1/sl unknown
- 2009-11-16 MX MX2011005100A patent/MX2011005100A/es active IP Right Grant
- 2009-11-16 RS RS20120569A patent/RS52598B/en unknown
- 2009-11-16 JP JP2011536567A patent/JP5746972B2/ja not_active Expired - Fee Related
- 2009-11-16 ES ES09752705T patent/ES2397218T3/es active Active
- 2009-11-16 AR ARP090104436A patent/AR074358A1/es not_active Application Discontinuation
- 2009-11-16 EP EP09752705A patent/EP2364308B1/en active Active
- 2009-11-16 NZ NZ592508A patent/NZ592508A/xx not_active IP Right Cessation
- 2009-11-16 PE PE2011001035A patent/PE20110581A1/es not_active Application Discontinuation
- 2009-11-16 PL PL09752705T patent/PL2364308T3/pl unknown
- 2009-11-16 PT PT97527055T patent/PT2364308E/pt unknown
- 2009-11-16 AU AU2009313768A patent/AU2009313768B2/en not_active Ceased
- 2009-11-16 DK DK09752705.5T patent/DK2364308T3/da active
- 2009-11-16 CA CA2742993A patent/CA2742993C/en not_active Expired - Fee Related
- 2009-11-16 US US12/619,574 patent/US8053438B2/en not_active Expired - Fee Related
- 2009-11-16 WO PCT/US2009/064637 patent/WO2010057121A1/en active Application Filing
- 2009-11-16 EA EA201100748A patent/EA019206B1/ru not_active IP Right Cessation
- 2009-11-16 BR BRPI0922095A patent/BRPI0922095A2/pt not_active IP Right Cessation
- 2009-11-16 KR KR1020117013506A patent/KR20110083746A/ko not_active Application Discontinuation
- 2009-11-16 CN CN200980154871.6A patent/CN102300860B/zh not_active Expired - Fee Related
-
2011
- 2011-03-07 US US13/042,410 patent/US8329700B2/en not_active Expired - Fee Related
- 2011-03-07 US US13/042,421 patent/US8247418B2/en not_active Expired - Fee Related
- 2011-05-04 IL IL212687A patent/IL212687A0/en unknown
- 2011-05-05 TN TN2011000221A patent/TN2011000221A1/fr unknown
- 2011-05-13 CL CL2011001094A patent/CL2011001094A1/es unknown
- 2011-06-10 MA MA33928A patent/MA32889B1/fr unknown
- 2011-06-14 CR CR20110326A patent/CR20110326A/es not_active Application Discontinuation
- 2011-06-14 CO CO11073978A patent/CO6382157A2/es not_active Application Discontinuation
-
2012
- 2012-02-27 HK HK12101965.5A patent/HK1161251A1/xx not_active IP Right Cessation
- 2012-06-22 US US13/531,453 patent/US20120277209A1/en not_active Abandoned
- 2012-12-19 SM SM201200061T patent/SMT201200061B/it unknown
- 2012-12-21 CY CY20121101246T patent/CY1113680T1/el unknown
-
2013
- 2013-01-22 HR HRP20130054AT patent/HRP20130054T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201100748A1 (ru) | Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10 | |
EA201291236A1 (ru) | Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10 | |
EA201100749A1 (ru) | Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10 | |
MX2008010671A (es) | Derivados de cinolina como inhibidores de fosfodiesterasa 10. | |
MX2008010953A (es) | Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10. | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
MX2010007392A (es) | Antagonistas de trpa1. | |
UA99882C2 (ru) | Производные бензофуранила, фармацевтическая композиция и способ лечения заболеваний (варианты) | |
MX2010007391A (es) | Antagonistas de trpa1. | |
TW200639166A (en) | Amino-pyridines as inhibitors of β-secretase | |
WO2012034116A3 (en) | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
UA99936C2 (en) | Biaryl substituted azabicyclic alkane derivatives | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
MX2008011258A (es) | Derivados de quinazolina como inhibidores de fosfodiesterasa 10. | |
MX2008011175A (es) | Inhibidores de fosfodiesterasa 10. | |
MX353257B (es) | Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1). | |
MX2009005935A (es) | Compuestos biciclicos y su uso como anti-diabeticos. | |
MX2010009654A (es) | Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. | |
WO2010147898A3 (en) | Small molecule inhibitors of spleen tyrosine kinase (syk) | |
MX2011010918A (es) | Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2. | |
WO2010062927A3 (en) | Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers | |
EA201171211A1 (ru) | Производные оксадиазола | |
MX340807B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
MY150600A (en) | Use of opioid antagonists for treating urinary retention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ RU |